Why Teva's Stock Could Crash Another 50% Post author:Sam Post published:November 7, 2017 Post category:BioPharma Teva continues to be battered by its massive debt load and struggling pipeline. Source: BioSpace You Might Also Like Pfizer and Genentech Duke it Out in Court over Herceptin Biosimilar Patents November 21, 2017 Filings Reveal Founder & CEO Buy Adds $570K to Retractable Tech Stake August 30, 2017 XW Laboratories Inc. Secures Over $17M Series B Financing Led By And September 19, 2017
